Journal of Veterinary Medical Science
Online ISSN : 1347-7439
Print ISSN : 0916-7250
ISSN-L : 0916-7250
Surgery
Clinical efficacy of anti-programmed death ligand 1 antibody HFC-L1/c4G12 in dogs with malignant tumors: an exploratory study
Satoshi TAKAGI, Michihito TAGAWA, Naoya MAEKAWA, Satoru KONNAI, Yumiko KAGAWA, Kenji HOSOYA, Akinori YAMAUCHI, Ayano KUDO, Shintaro KAMO, Sangho KIM, Ryohei KINOSHITA, Tatsuya DEGUCHI, Ryo OWAKI, Yurika TACHIBANA, Madoka YOKOKAWA, Hiroto TAKEUCHI, Hayato NAKAMURA, Yukinari KATO, Shigeki KANAZAWA, Tomoyuki ABE, Takuya FURUTA, Keiichi YAMAMOTO, Yasuhiko SUZUKI, Tomohiro OKAGAWA, Shiro MURATA, Kazuhiko OHASHI
Author information
JOURNAL OPEN ACCESS
Supplementary material

2025 Volume 87 Issue 12 Pages 1419-1425

Details
Abstract

Cancer in dogs remains a major challenge in modern veterinary medicine. Immunotherapy using immune checkpoint inhibitors (ICIs) is available for various human tumor types, and recent veterinary clinical studies have shown that ICIs are a promising approach for treating canine cancers. A canine chimeric anti-PD-L1 antibody, c4G12 (HFC-L1), has been investigated for canine cancer immunotherapy; however, its clinical benefits have not been well characterized in tumors other than pulmonary metastatic (stage IV) oral malignant melanoma (OMM). To explore the efficacy and safety of HFC-L1, we conducted a clinical study in dogs with stage I–III OMM or other tumor types (n=12). HFC-L1 treatment at a dose of 5 mg/kg every 2 weeks was well tolerated, and no grade 3 or higher treatment-related adverse events were reported. Among the dogs eligible for response evaluation (n=10), a partial response was observed in one dog with squamous cell carcinoma, resulting in an objective response rate of 10%. In addition, in a dog with ceruminous cell carcinoma, clinical evidence of a tumor response was observed in metastatic lung lesions. Together, these results suggest that the HFC-L1 therapy is applicable for the treatment of various tumor types, although its clinical benefits should be further evaluated in clinical studies involving a larger number of dogs with each tumor type.

Content from these authors
© 2025 by the Japanese Society of Veterinary Science

This article is licensed under a Creative Commons [Attribution-NonCommercial-NoDerivatives 4.0 International] license.
https://creativecommons.org/licenses/by-nc-nd/4.0/
Previous article Next article
feedback
Top